Keywords: newron, completes, ph, iii, safinamide, enrollment, pharmaceuticals

Newron completes Ph III safinamide enrollment

Article | 26 May 2008

Print This

Newron Pharmaceuticals, an Italian company focused on novel central nervous system and pain therapies, says that patient enrollment has been ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in